Selected research
Industry Research
OTC Anti-Infective Products Industry Research Report 2026
Market perspective
The global OTC Anti-Infective Products market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for OTC Anti-Infective Products is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for OTC Anti-Infective Products is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for OTC Anti-Infective Products is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of OTC Anti-Infective Products include Teva, Johnson & Johnson, NOVARTIS, MYLAN, Roche, Lingrui, Pfizer, CR SANJIU and GSK, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global OTC Anti-Infective Products market in terms of revenue (US$ million) and, where applicable, sales volume (M Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/M Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
OTC Anti-Infective Products Market by Company
Teva
Johnson & Johnson
NOVARTIS
MYLAN
Roche
Lingrui
Pfizer
CR SANJIU
GSK
Bayer
Sun Pharma
Gilead Sciences
Cipla
Bausch Health
Astellas Pharma
OTC Anti-Infective Products Segment by Type
Antiviral
Antibacterial
Antifungal
Antiseptics
Others
OTC Anti-Infective Products Segment by Application
Retail Pharmacies
Online Pharmacies
Hospital Pharmacies
OTC Anti-Infective Products Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global OTC Anti-Infective Products market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of OTC Anti-Infective Products and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of OTC Anti-Infective Products.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of OTC Anti-Infective Products manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of OTC Anti-Infective Products by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of OTC Anti-Infective Products in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Antiviral
- Antibacterial
- Antifungal
- Antiseptics
- Others
Applications
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
Companies covered
- Teva
- Johnson & Johnson
- NOVARTIS
- MYLAN
- Roche
- Lingrui
- Pfizer
- CR SANJIU
- GSK
- Bayer
- Sun Pharma
- Gilead Sciences
- Cipla
- Bausch Health
- Astellas Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global OTC Anti-Infective Products Market Size (2021-2032)
- 2.2.2 Global OTC Anti-Infective Products Sales (2021-2032)
- 2.2.3 Global OTC Anti-Infective Products Market Average Price (2021-2032)
- 2.3 OTC Anti-Infective Products by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Antiviral
- 2.3.3 Antibacterial
- 2.3.4 Antifungal
- 2.3.5 Antiseptics
- 2.3.6 Others
- 2.4 OTC Anti-Infective Products by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Retail Pharmacies
- 2.4.3 Online Pharmacies
- 2.4.4 Hospital Pharmacies
3 Market Competitive Landscape by Manufacturers
- 3.1 Global OTC Anti-Infective Products Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global OTC Anti-Infective Products Sales (M Units) of Manufacturers (2021-2026)
- 3.3 Global OTC Anti-Infective Products Revenue of Manufacturers (2021-2026)
- 3.4 Global OTC Anti-Infective Products Average Price by Manufacturers (2021-2026)
- 3.5 Global OTC Anti-Infective Products Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of OTC Anti-Infective Products, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of OTC Anti-Infective Products, Product Type & Application
- 3.8 Global Manufacturers of OTC Anti-Infective Products, Established Date
- 3.9 Global OTC Anti-Infective Products Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva
- 4.1.1 Teva Company Information
- 4.1.2 Teva Business Overview
- 4.1.3 Teva OTC Anti-Infective Products Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva OTC Anti-Infective Products Product Portfolio
- 4.1.5 Teva Recent Developments
- 4.2 Johnson & Johnson
- 4.2.1 Johnson & Johnson Company Information
- 4.2.2 Johnson & Johnson Business Overview
- 4.2.3 Johnson & Johnson OTC Anti-Infective Products Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Johnson & Johnson OTC Anti-Infective Products Product Portfolio
- 4.2.5 Johnson & Johnson Recent Developments
- 4.3 NOVARTIS
- 4.3.1 NOVARTIS Company Information
- 4.3.2 NOVARTIS Business Overview
- 4.3.3 NOVARTIS OTC Anti-Infective Products Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 NOVARTIS OTC Anti-Infective Products Product Portfolio
- 4.3.5 NOVARTIS Recent Developments
- 4.4 MYLAN
- 4.4.1 MYLAN Company Information
- 4.4.2 MYLAN Business Overview
- 4.4.3 MYLAN OTC Anti-Infective Products Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 MYLAN OTC Anti-Infective Products Product Portfolio
- 4.4.5 MYLAN Recent Developments
- 4.5 Roche
- 4.5.1 Roche Company Information
- 4.5.2 Roche Business Overview
- 4.5.3 Roche OTC Anti-Infective Products Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Roche OTC Anti-Infective Products Product Portfolio
- 4.5.5 Roche Recent Developments
- 4.6 Lingrui
- 4.6.1 Lingrui Company Information
- 4.6.2 Lingrui Business Overview
- 4.6.3 Lingrui OTC Anti-Infective Products Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Lingrui OTC Anti-Infective Products Product Portfolio
- 4.6.5 Lingrui Recent Developments
- 4.7 Pfizer
- 4.7.1 Pfizer Company Information
- 4.7.2 Pfizer Business Overview
- 4.7.3 Pfizer OTC Anti-Infective Products Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Pfizer OTC Anti-Infective Products Product Portfolio
- 4.7.5 Pfizer Recent Developments
- 4.8 CR SANJIU
- 4.8.1 CR SANJIU Company Information
- 4.8.2 CR SANJIU Business Overview
- 4.8.3 CR SANJIU OTC Anti-Infective Products Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 CR SANJIU OTC Anti-Infective Products Product Portfolio
- 4.8.5 CR SANJIU Recent Developments
- 4.9 GSK
- 4.9.1 GSK Company Information
- 4.9.2 GSK Business Overview
- 4.9.3 GSK OTC Anti-Infective Products Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 GSK OTC Anti-Infective Products Product Portfolio
- 4.9.5 GSK Recent Developments
- 4.10 Bayer
- 4.10.1 Bayer Company Information
- 4.10.2 Bayer Business Overview
- 4.10.3 Bayer OTC Anti-Infective Products Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Bayer OTC Anti-Infective Products Product Portfolio
- 4.10.5 Bayer Recent Developments
- 4.11 Sun Pharma
- 4.11.1 Sun Pharma Company Information
- 4.11.2 Sun Pharma Business Overview
- 4.11.3 Sun Pharma OTC Anti-Infective Products Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Sun Pharma OTC Anti-Infective Products Product Portfolio
- 4.11.5 Sun Pharma Recent Developments
- 4.12 Gilead Sciences
- 4.12.1 Gilead Sciences Company Information
- 4.12.2 Gilead Sciences Business Overview
- 4.12.3 Gilead Sciences OTC Anti-Infective Products Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Gilead Sciences OTC Anti-Infective Products Product Portfolio
- 4.12.5 Gilead Sciences Recent Developments
- 4.13 Cipla
- 4.13.1 Cipla Company Information
- 4.13.2 Cipla Business Overview
- 4.13.3 Cipla OTC Anti-Infective Products Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Cipla OTC Anti-Infective Products Product Portfolio
- 4.13.5 Cipla Recent Developments
- 4.14 Bausch Health
- 4.14.1 Bausch Health Company Information
- 4.14.2 Bausch Health Business Overview
- 4.14.3 Bausch Health OTC Anti-Infective Products Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Bausch Health OTC Anti-Infective Products Product Portfolio
- 4.14.5 Bausch Health Recent Developments
- 4.15 Astellas Pharma
- 4.15.1 Astellas Pharma Company Information
- 4.15.2 Astellas Pharma Business Overview
- 4.15.3 Astellas Pharma OTC Anti-Infective Products Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Astellas Pharma OTC Anti-Infective Products Product Portfolio
- 4.15.5 Astellas Pharma Recent Developments
5 Global OTC Anti-Infective Products Market Scenario by Region
- 5.1 Global OTC Anti-Infective Products Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global OTC Anti-Infective Products Sales by Region: 2021-2032
- 5.2.1 Global OTC Anti-Infective Products Sales by Region: 2021-2026
- 5.2.2 Global OTC Anti-Infective Products Sales by Region: 2027-2032
- 5.3 Global OTC Anti-Infective Products Revenue by Region: 2021-2032
- 5.3.1 Global OTC Anti-Infective Products Revenue by Region: 2021-2026
- 5.3.2 Global OTC Anti-Infective Products Revenue by Region: 2027-2032
- 5.4 North America OTC Anti-Infective Products Market Facts & Figures by Country
- 5.4.1 North America OTC Anti-Infective Products Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America OTC Anti-Infective Products Sales by Country (2021-2032)
- 5.4.3 North America OTC Anti-Infective Products Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe OTC Anti-Infective Products Market Facts & Figures by Country
- 5.5.1 Europe OTC Anti-Infective Products Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe OTC Anti-Infective Products Sales by Country (2021-2032)
- 5.5.3 Europe OTC Anti-Infective Products Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific OTC Anti-Infective Products Market Facts & Figures by Country
- 5.6.1 Asia Pacific OTC Anti-Infective Products Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific OTC Anti-Infective Products Sales by Country (2021-2032)
- 5.6.3 Asia Pacific OTC Anti-Infective Products Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America OTC Anti-Infective Products Market Facts & Figures by Country
- 5.7.1 South America OTC Anti-Infective Products Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America OTC Anti-Infective Products Sales by Country (2021-2032)
- 5.7.3 South America OTC Anti-Infective Products Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa OTC Anti-Infective Products Market Facts & Figures by Country
- 5.8.1 Middle East and Africa OTC Anti-Infective Products Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa OTC Anti-Infective Products Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa OTC Anti-Infective Products Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global OTC Anti-Infective Products Sales by Type (2021-2032)
- 6.1.1 Global OTC Anti-Infective Products Sales by Type (2021-2032) & (M Units)
- 6.1.2 Global OTC Anti-Infective Products Sales Market Share by Type (2021-2032)
- 6.2 Global OTC Anti-Infective Products Revenue by Type (2021-2032)
- 6.2.1 Global OTC Anti-Infective Products Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global OTC Anti-Infective Products Revenue Market Share by Type (2021-2032)
- 6.3 Global OTC Anti-Infective Products Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global OTC Anti-Infective Products Sales by Application (2021-2032)
- 7.1.1 Global OTC Anti-Infective Products Sales by Application (2021-2032) & (M Units)
- 7.1.2 Global OTC Anti-Infective Products Sales Market Share by Application (2021-2032)
- 7.2 Global OTC Anti-Infective Products Revenue by Application (2021-2032)
- 7.2.1 Global OTC Anti-Infective Products Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global OTC Anti-Infective Products Revenue Market Share by Application (2021-2032)
- 7.3 Global OTC Anti-Infective Products Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 OTC Anti-Infective Products Value Chain Analysis
- 8.1.1 OTC Anti-Infective Products Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 OTC Anti-Infective Products Production Mode & Process
- 8.2 OTC Anti-Infective Products Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 OTC Anti-Infective Products Distributors
- 8.2.3 OTC Anti-Infective Products Customers
9 Global OTC Anti-Infective Products Analyzing Market Dynamics
- 9.1 OTC Anti-Infective Products Industry Trends
- 9.2 OTC Anti-Infective Products Industry Drivers
- 9.3 OTC Anti-Infective Products Industry Opportunities and Challenges
- 9.4 OTC Anti-Infective Products Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst